Curanex Pharmaceuticals Inc (CURX) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is led by CEO Jun Liu, headquartered in US, publicly traded since 2025.
Curanex Pharmaceuticals Inc (CURX) stock trades at $4.64 with a market capitalization of $7.28M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.64, reflecting a net loss over the last twelve months, price-to-book of 1.40, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.58 and $16.94, and currently trades 72.6% below its 52-week high.
On profitability, Curanex Pharmaceuticals Inc generates a return on equity (ROE) of -109.11% (negative, reflecting a net loss), return on capital employed of -212.35%.
Curanex Pharmaceuticals Inc by the numbers, 2022–2025
Between 2022 and 2025 Curanex Pharmaceuticals Inc reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-4.0M in 2025.
On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-10.0M.
Borrowings stand at $0, cash from operations was $-10.0M in the latest year, positive in 0 of the last 4.
Return on equity has averaged -18.2% over five years, and was -36.4% in the most recent year.
The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.
Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.
Curanex Pharmaceuticals Inc (CURX) — frequently asked questions
What is Curanex Pharmaceuticals Inc (CURX) stock price today?
Curanex Pharmaceuticals Inc (CURX) is currently trading at $4.64, down 10.77% today.
What is CURX P/E ratio?
Curanex Pharmaceuticals Inc's P/E ratio is -0.64. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.
What is CURX return on equity (ROE)?
Curanex Pharmaceuticals Inc's return on equity (ROE) is -109.11%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.
What is Curanex Pharmaceuticals Inc's market cap?
Curanex Pharmaceuticals Inc has a market capitalization of $7.28M.
Does CURX pay a dividend?
Curanex Pharmaceuticals Inc is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.
How much debt does CURX carry?
Curanex Pharmaceuticals Inc has a debt-to-equity ratio of 0.06. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.
What is CURX's profit margin?
Curanex Pharmaceuticals Inc reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.
What sector is CURX in?
Curanex Pharmaceuticals Inc is classified under Healthcare, in the Biotechnology industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.
Which exchange is CURX listed on?
Curanex Pharmaceuticals Inc trades on NCM under the ticker CURX.
What is CURX's 52-week range?
Over the last year Curanex Pharmaceuticals Inc has traded between $3.58 and $16.94.
Related Healthcare Stocks
Popular Stocks
Screens CURX currently matches
On the figures above, Curanex Pharmaceuticals Inc passes the filters for 3 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Nano Cap Stocks. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.